Science Corp Implants Vision-Restoring Prima Retinal Chip in Human Trial

Neural engineering startup Science Corporation, led by former Neuralink president Max Hodak, announced landmark clinical results from its pivotal European clinical trial evaluating the Prima retinal implant. As reported across The Verge's science coverage, the wireless photovoltaic subretinal microchip successfully restored functional central visual acuity to 38 patients suffering from severe blindness caused by geographic atrophy from age-related macular degeneration.

The breakthrough represents one of the most significant clinical milestones in bioelectronic medicine and visual neuroprosthetics in decades. Patients who previously experienced complete central blind spots were able to read sequential letters, identify household objects, and navigate indoor environments with a clinically verified average improvement of 23 visual letters on standardized eye evaluation charts.

Photovoltaic subretinal chip engineering

The core of the Prima platform is an ultra-miniature, wireless photovoltaic microchip measuring just two millimeters by two millimeters and only thirty micrometers in thickness—roughly one-third the thickness of a human hair. The implant contains 378 individual micro-photodiodes, each functioning as an autonomous pixel that converts beamed infrared light directly into precise electrical pulses that stimulate surviving retinal bipolar and ganglion cells.

Unlike older visual prostheses such as Argus II that required invasive external cables, trans-scleral connectors, and high-voltage inductive power coils, the Prima chip is completely wireless and self-powered. It relies entirely on near-infrared illumination projected through the pupil from external smart glasses, eliminating mechanical tethering and significantly reducing long-term surgical rejection and tissue erosion risks.

Human clinical trial protocols and methodology

The clinical trial, named the PRIMAvera study, enrolled 38 blind participants across leading ophthalmic surgery centers in France, Germany, Italy, and the United Kingdom. All enrolled patients had lost central vision due to late-stage geographic atrophy, an irreversible degenerative condition that destroys photoreceptor cells in the macula while leaving deeper retinal neural circuits intact.

Ophthalmic surgeons implanted the tiny chip beneath the central macula through a delicate, minimally invasive outpatient vitrectomy procedure lasting under ninety minutes. Following surgical recovery, patients were fitted with customized eyewear equipped with an outward-facing digital camera, a pocket-sized visual processing computer, and an eye-tracking infrared projection system calibrated to patient gaze direction.

Quantitative visual recovery metrics

The primary clinical endpoint evaluated visual acuity recovery twelve months post-implantation using the standardized Early Treatment Diabetic Retinopathy Study letter chart. Patients achieved a mean visual acuity improvement of 23 letters (0.46 logMAR), equivalent to regaining nearly five full lines of functional sight on a standard medical eye chart.

Several trial participants demonstrated exceptional visual rehabilitation, achieving up to 32 letters of improvement and reaching a visual acuity level of 20/160. Patients successfully demonstrated the ability to read printed sentences, recognize face contours, and play board games, marking the first time in medical history that an electronic retinal prosthesis restored form vision with real letter recognition in atrophic macular degeneration.

Regulatory roadmap and commercial availability

Following the successful European clinical validation, Science Corporation confirmed that it has initiated regulatory filings with the European Medicines Agency to secure CE Mark market authorization for the Prima system. The company is concurrently preparing submissions to the United States Food and Drug Administration under the Breakthrough Device designation program to commence pivotal commercial trials.

Hodak indicated that commercial production scaling is underway at Science Corp's California manufacturing facility, aiming for broader clinical availability by early 2027. The company is also collaborating with major healthcare insurance providers and national medical reimbursement authorities across Europe to establish clinical coverage pathways for eligible ophthalmic patients.

What to watch on neural visual prosthetics

The clinical success of Science Corporation's Prima implant validates the viability of bioelectronic interfaces that restore lost sensory perception by directly stimulating surviving biological neural networks. By decoupling power transmission from visual signal projection, the platform proves that wireless micro-photovoltaic arrays can operate safely in human tissue over multi-year durations.

As neural interface competitors including Neuralink and Precision Neuroscience pursue cortical brain implants for motor and sensory paralysis, Science Corp's subretinal focus delivers immediate, life-altering visual restoration through a far less invasive surgical pathway. Future software updates to the pocket vision processor promise to deliver digital zoom, edge-contrast enhancement, and real-time text narration directly into the user's field of view.